Trials / Completed
CompletedNCT02358096
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Astellas Pharma Europe B.V. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of ASP8232 in reducing Urinary Albumin to Creatinine Ratio (UACR) in subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) at 12 weeks compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP8232 | oral capsule |
| DRUG | Placebo | oral capsule |
Timeline
- Start date
- 2015-03-17
- Primary completion
- 2016-10-26
- Completion
- 2017-03-15
- First posted
- 2015-02-06
- Last updated
- 2024-10-31
Locations
57 sites across 9 countries: Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02358096. Inclusion in this directory is not an endorsement.